Biomerica Inc (BMRA) - Total Assets
Based on the latest financial reports, Biomerica Inc (BMRA) holds total assets worth $4.88 Million USD as of February 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Check BMRA cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Biomerica Inc - Total Assets Trend (1986–2025)
This chart illustrates how Biomerica Inc's total assets have evolved over time, based on quarterly financial data. Explore BMRA strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Biomerica Inc - Asset Composition Analysis
Current Asset Composition (May 2025)
Biomerica Inc's total assets of $4.88 Million consist of 82.0% current assets and 18.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 40.4% |
| Accounts Receivable | $731.00K | 12.3% |
| Inventory | $1.49 Million | 25.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $228.00K | 3.8% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (1986–2025)
This chart illustrates how Biomerica Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Biomerica Inc stock valuation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Biomerica Inc's current assets represent 82.0% of total assets in 2025, a decrease from 94.7% in 1986.
- Cash Position: Cash and equivalents constituted 40.4% of total assets in 2025, down from 82.7% in 1986.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, an increase from 0.0% in 1986.
- Asset Diversification: The largest asset category is inventory at 25.1% of total assets.
Biomerica Inc Competitors by Total Assets
Key competitors of Biomerica Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Cochlear Ltd
AU:COH
|
Australia | AU$2.83 Billion |
|
Shenzhen New Industries Biomedical
SHE:300832
|
China | CN¥9.58 Billion |
|
Jafron Biomedical Co Ltd
SHE:300529
|
China | CN¥5.52 Billion |
|
HOB Biotech Group Corp Ltd
SHG:688656
|
China | CN¥912.83 Million |
|
Polynovo Ltd
AU:PNV
|
Australia | AU$123.37 Million |
|
Shanghai ZJ Bio-Tech Co. Ltd. A
SHG:688317
|
China | CN¥3.71 Billion |
|
Dirui Industrial Co Ltd
SHE:300396
|
China | CN¥2.62 Billion |
|
Emvision Medical Devices Ltd
AU:EMV
|
Australia | AU$24.94 Million |
Biomerica Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 2.64 | 3.76 | 7.10 |
| Quick Ratio | 1.59 | 2.76 | 4.63 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $2.56 Million | $4.55 Million | $7.93 Million |
Biomerica Inc - Advanced Valuation Insights
This section examines the relationship between Biomerica Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.91 |
| Latest Market Cap to Assets Ratio | 1.02 |
| Asset Growth Rate (YoY) | -35.8% |
| Total Assets | $5.95 Million |
| Market Capitalization | $6.09 Million USD |
Valuation Analysis
Above Book Valuation: The market values Biomerica Inc's assets above their book value (1.02x), reflecting positive investor sentiment about the company's future prospects.
Significant Asset Reduction: Biomerica Inc's assets decreased by 35.8% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Biomerica Inc (1986–2025)
The table below shows the annual total assets of Biomerica Inc from 1986 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-05-31 | $5.95 Million | -35.76% |
| 2024-05-31 | $9.25 Million | -35.98% |
| 2023-05-31 | $14.45 Million | +27.08% |
| 2022-05-31 | $11.37 Million | -3.76% |
| 2021-05-31 | $11.82 Million | -31.52% |
| 2020-05-31 | $17.26 Million | +229.05% |
| 2019-05-31 | $5.25 Million | +0.44% |
| 2018-05-31 | $5.22 Million | +4.08% |
| 2017-05-31 | $5.02 Million | -12.37% |
| 2016-05-31 | $5.73 Million | -6.50% |
| 2015-05-31 | $6.12 Million | -5.35% |
| 2014-05-31 | $6.47 Million | +1.18% |
| 2013-05-31 | $6.39 Million | +14.79% |
| 2012-05-31 | $5.57 Million | +12.42% |
| 2011-05-31 | $4.96 Million | -1.19% |
| 2010-05-31 | $5.02 Million | -2.66% |
| 2009-05-31 | $5.15 Million | +0.87% |
| 2008-05-31 | $5.11 Million | +58.40% |
| 2007-05-31 | $3.22 Million | +32.79% |
| 2006-05-31 | $2.43 Million | -58.07% |
| 2005-05-31 | $5.79 Million | +4.00% |
| 2004-05-31 | $5.57 Million | +0.36% |
| 2003-05-31 | $5.55 Million | +5.14% |
| 2002-05-31 | $5.28 Million | -1.32% |
| 2001-05-31 | $5.35 Million | -20.61% |
| 2000-05-31 | $6.74 Million | -13.65% |
| 1999-05-31 | $7.80 Million | +4.00% |
| 1998-05-31 | $7.50 Million | +1.35% |
| 1997-05-31 | $7.40 Million | +21.31% |
| 1996-05-31 | $6.10 Million | +5.17% |
| 1995-05-31 | $5.80 Million | -7.94% |
| 1994-05-31 | $6.30 Million | 0.00% |
| 1993-05-31 | $6.30 Million | -1.56% |
| 1992-05-31 | $6.40 Million | -12.33% |
| 1991-05-31 | $7.30 Million | -18.89% |
| 1990-05-31 | $9.00 Million | +136.84% |
| 1989-05-31 | $3.80 Million | -20.83% |
| 1988-05-31 | $4.80 Million | -23.81% |
| 1987-05-31 | $6.30 Million | -16.00% |
| 1986-05-31 | $7.50 Million | -- |
About Biomerica Inc
Biomerica, Inc., a biomedical technology company, engages in developing, patenting, manufacturing, and marketing diagnostic and therapeutic products for the detection and treatment of medical conditions and diseases worldwide. The company's diagnostic test kits are used to analyze blood, urine, nasal or fecal specimens from patients in the diagnosis of various diseases, food intolerances, and oth… Read more